|
|
| Line 1: |
Line 1: |
| ===Pharmacokinetics=== | | ===Pharmacokinetics=== |
| | | <table style="background: cellspacing="0px" align="" cellpadding="0px" width="50%"> |
| {| class="wikitable" border="1" width="40%" style="text-align:center"
| | <tr> |
| |-
| | <td style="width:auto; vertical-align:top;border-width:0px; border-style:inset"> |
| ! colspan="6" align="center"| VEGFR Inhibitor [[Pharmacokinetics]] <ref>D. Smith et al. Br J Clin Pharmacol. 2009 April; 67(4): 421–426.</ref><ref>R. Khosravan, et al. General Poster Session, Developmental Therapeutics: Cytotoxic Chemotherapy, J Clin Oncol 26: 2008 (May 20 suppl; abstr 2578)</ref><ref>PMID:16133532</ref><ref>PMID:20821331</ref><ref>PMID:20717111</ref>
| | <div style="overflow:auto; height:100%; width: 100%"> |
| |-
| | {{:Tyrosine Kinase Inhibitor Pharmacokinetics}} |
| ! Parameter
| | </div> |
| ! [[Sunitinib]] (Sutent)
| | </td> |
| ! [[Sorafenib]] (Nexavar)
| | </tr> |
| |-
| | </table> |
| ! [[Pharmacokinetics#Tmax|T<sub>max</sub>]] (hr)
| |
| ! 8
| |
| ! 8.3
| |
| |-
| |
| ! [[Pharmacokinetics#Cmax|C<sub>max</sub>]] (ng/ml)
| |
| ! 24.6
| |
| ! 460
| |
| |-
| |
| ! [[Pharmacokinetics#Bioavailability_.28F.29|Bioavailability]] (%)
| |
| ! Variable
| |
| ! 29-49
| |
| |-
| |
| ! [[Pharmacokinetics#Protein_Binding|Protein Binding]] (%)
| |
| ! 95
| |
| ! 99
| |
| |-
| |
| ! [[Pharmacokinetics#Half_Life_.28T1.2F2.29|T<sub>1/2</sub>]] (hr)
| |
| ! 83
| |
| ! 29
| |
| |-
| |
| ! [[Pharmacokinetics#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr)
| |
| ! 1921
| |
| ! 11040
| |
| |-
| |
| ! Dosage (mg)
| |
| ! 50
| |
| ! 50
| |
| |-
| |
| ! Metabolism
| |
| ! Hepatic (CYP3A4)
| |
| ! Hepatic (CYP3A4)
| |
| |}
| |
